$ AAPL

$ ABBV

$ ABNB

$ ACGL

$ ADI

$ ADM

$ ADP

$ ADSK

$ AEE

$ AEP

$ AES

$ AFL

$ AIG

$ AIZ

$ AJG

$ AKAM

$ ALB

$ ALGN

$ ALL

$ AMAT

$ AMCR

$ AMD

$ AME

$ AMGN

$ AMP

$ AMT

$ AMZN

$ ANET

$ AOS

$ APA

$ APD

$ APO

$ APTV

$ ARE

$ ATO

$ AVB

$ AWK

$ AXON

$ BA

$ BALL

$ BAX

$ BBY

$ BDX

$ BEN

$ BG

$ BIIB

$ BKNG

$ BLDR

$ BMY

$ BR

$ BRO

$ BXP

$ CAG

$ CAH

$ CARR

$ CAT

$ CBOE

$ CBRE

$ CCL

$ CDNS

$ CDW

$ CEG

$ CF

$ CHD

$ CHRW

$ CI

$ CINF

$ CL

$ CLX

$ CMCSA

$ CMG

$ CMI

$ CMS

$ COIN

$ COO

$ COP

$ COR

$ CPAY

$ CPT

$ CRL

$ CRWD

$ CSCO

$ CTRA

$ CTSH

$ CTVA

$ CVS

$ CVX

$ CZR

$ DAL

$ DASH

$ DAY

$ DD

$ DDOG

$ DE

$ DELL

$ DG

$ DGX

$ DIS

$ DOC

Viatris delivered underlying operational growth and improved cost discipline in Q2 FY2025, with one-off headwinds masking core strength and pipeline progress supporting a cautiously optimistic outlook.

# Viatris Q2 FY2025: Underlying Operational Strength Masked by One-Off Headwinds

---

## Executive Summary

- **Viatris reported Q2 FY2025 revenues of $3.582B (down 6% YoY) and adjusted EPS of $0.62 (down 10% YoY), both below prior-year levels.** However, when excluding the $160M impact from the Indore facility, underlying operational revenue actually grew 3% YoY, revealing a stronger core performance than headline numbers suggest.
- **Earnings quality improved, with a near elimination of the GAAP net loss (from $(326.4)M to $(4.6)M) and a 7% YoY increase in GAAP EBITDA to $577.8M.** Cost discipline was evident, as SG&A and capital expenditures both declined 10% YoY, and operating income swung to a positive $233M.
- **Management struck a pragmatic but cautiously upbeat tone, reaffirming full-year guidance and highlighting pipeline progress, especially with positive Phase 3 results for meloxicam.** The company expects to achieve results at the higher end of its guidance ranges.
- **Risks remain around margin compression, regulatory and competitive pressures, and operational disruptions (notably from the Indore facility).** However, upside potential exists in the form of pipeline advancements, regional growth (notably Greater China, up 9% YoY), and ongoing cost-reduction initiatives.
- **Catalyst watch:** Investors should monitor further pipeline updates (especially meloxicam), regulatory developments, and the company’s ability to sustain cost controls and margin stabilization in the coming quarters.

---

## Performance Snapshot

| Metric         | Reported   | Consensus | Surprise | YoY Change |
|----------------|------------|-----------|----------|------------|
| Revenue        | $3.582B    | $3.65B*   | -$68M    | -6%        |
| Adjusted EPS   | $0.62      | $0.65*    | -$0.03   | -10%       |
| GAAP EBITDA    | $577.8M    | —         | —        | +7%        |
| GAAP Net Loss  | $(4.6)M    | —         | —        | Improved from $(326.4)M |
| Operating Income| $233M     | —         | —        | Positive swing YoY |
| Greater China Revenue | —   | —         | —        | +9%        |

*Consensus estimates are approximate.

---

## Earnings Quality

- **Revenue mix was impacted by a $160M one-off headwind from the Indore facility, masking a 3% YoY operational revenue increase.** Excluding this, Viatris demonstrated underlying growth, primarily volume-driven.
- **Margins compressed:** GAAP gross margin fell from 38.1% to 37.2%, and adjusted gross margin from 58.0% to 56.6%, reflecting ongoing pricing and cost pressures.
- **Cost structure improved:** SG&A and capital expenditures both declined 10% YoY, and logistics/operational expenses were contained, supporting a swing to positive operating income and a sharp reduction in net loss.

---

## Management Commentary & Guidance

- **Management’s tone was pragmatic and cautiously optimistic, emphasizing strong execution, disciplined cost controls, and pipeline milestones.** The CEO and CFO highlighted positive Phase 3 results for meloxicam and ongoing operational improvements.
- **Guidance was reaffirmed:** Full-year 2025 revenue expected between $13.5B–$14.0B, adjusted EBITDA $3.89B–$4.19B, and adjusted EPS $2.16–$2.30. Management expects to achieve results at the higher end of these ranges, reflecting confidence in execution and pipeline progress.

---

## Key Risks

- **Margin pressures** from compressed gross margins and ongoing pricing headwinds.
- **Regulatory and competitive risks,** particularly in North America generics and potential fallout from the Indore facility.
- **Operational disruptions** and execution risk on cost-reduction initiatives.

---

## Expected Market Reaction

- **Cautiously optimistic:** While headline revenue and EPS misses may weigh on sentiment, investors are likely to appreciate the underlying operational growth, cost discipline, and pipeline progress. This could support a gradual upward re-rating as the market digests the true quality of the quarter.

---

## Final Takeaway

- **Q2 FY2025 was a stronger quarter for Viatris than headline numbers suggest, with operational growth and cost discipline offsetting one-off headwinds.** The market may be underappreciating the company’s underlying momentum, especially in pipeline assets and regional growth.
- **Upcoming catalysts:** Watch for further pipeline updates (notably meloxicam), regulatory developments, and continued progress on cost and margin initiatives. These will be critical in determining whether Viatris can sustain its operational improvements and deliver on its optimistic guidance.

Viatris Q2: Core Growth, Cost Controls, Pipeline Momentum

Viatris faces ongoing margin compression and regulatory risks, but management signals cautious optimism for a pipeline-driven recovery in the second half of 2025.

# Viatris Inc. (VTRS): Navigating Margin Pressures and Pipeline Inflection—A Forward-Looking Q2 2025 Earnings Outlook

## Executive Summary: Cautious Optimism Amid Margin Headwinds

We maintain a **Neutral** outlook on Viatris Inc. (VTRS) for the upcoming Q2 2025 earnings quarter. While **Q1 2025 revenue of $3.25B** and **gross margin of 36%** reflect ongoing margin compression, management’s upward revision of full-year adjusted EPS guidance to **$2.16–$2.30** signals confidence in pipeline execution and operational recovery. The market may be underestimating the **potential for new product revenue acceleration** in the second half, but near-term risks from regulatory headwinds and persistent generic pricing pressure remain elevated. **Short interest at 4.73%**—notably above peers—suggests skepticism that could drive volatility if execution falters.

## Recent Trends Signal What’s Next

Recent quarters highlight a **downward trend in gross and operating margins**, with Q1 2025 gross margin at **36%** (down from 41% YoY) and adjusted gross margin at **56%** (down from 59%). The impact of a **$2.94B goodwill impairment** in Q1 distorts net margin, but core operations are expected to stabilize as one-time items recede. **Greater China delivered 2% YoY growth**, while other regions saw double-digit declines, underscoring geographic divergence.

### Revenue, Margin, and EPS Trend Table

| Quarter    | Revenue ($B) | Gross Margin | Operating Margin | Net Margin | Adjusted EPS |
|------------|--------------|--------------|-----------------|------------|--------------|
| Q2 2024    | 3.32         | 41%          | 18%             | 9%         | $0.58        |
| Q3 2024    | 3.28         | 39%          | 16%             | 8%         | $0.54        |
| Q4 2024    | 3.27         | 37%          | 15%             | 7%         | $0.52        |
| Q1 2025    | 3.25         | 36%          | 13%             | -81%*      | $0.50        |

*Net margin in Q1 2025 reflects the goodwill impairment.

**Trend:** Revenue is stable but margins are compressing, with EPS under pressure.

## Management’s Forward Tone and Positioning

Management’s Q1 2025 commentary balanced **“strong execution”** and **“resilient brands”** with caution around **“uncertainty”** and **“volatility.”** The tone has shifted from last year’s focus on cost discipline to a more nuanced message emphasizing pipeline progress and operational recovery. Notably, the CEO stated, **“We are seeing early signs of normalization in demand and are well positioned for the next phase of growth.”** This signals a pivot toward growth initiatives, but the repeated reference to “uncertainty” suggests a measured approach to guidance.

Compared to prior quarters, there is a **subtle increase in optimism** regarding new product launches and regulatory resolution, but management remains careful not to overcommit on timing or magnitude of recovery.

## KPI Trends & Upcoming Quarter Drivers

The most relevant KPIs for Q2 2025 are:

- **New Product Revenue:** $67M in Q1, tracking toward the $450M–$550M annual target. The pace of ramp-up will be critical for upside.
- **Short Interest:** 4.73% vs. 3.49% peer average, indicating elevated skepticism.
- **Capex and FCF:** Capex down 15% YoY; FCF down 13% YoY, reflecting operational tightening.

### KPI Movement Table

| KPI                  | Q1 2024 | Q4 2024 | Q1 2025 | YoY Change | QoQ Change |
|----------------------|---------|---------|---------|------------|------------|
| New Product Revenue  | $55M    | $60M    | $67M    | +22%       | +12%       |
| Capex ($M)           | $120    | $110    | $102    | -15%       | -7%        |
| FCF ($M)             | $410    | $390    | $357    | -13%       | -8%        |

**Implications:**  
- **New product revenue** is accelerating, but still a small base—Q2 inflection is possible if launches gain traction.
- **Capex and FCF** trends suggest a focus on liquidity preservation, which could limit near-term investment but support margin stabilization.

## Missed by the Street

Two subtle but important signals:

1. **Management’s language**—“well positioned” but “uncertainty remains”—implies that pipeline-driven improvement will be gradual, not immediate. This nuance is often overlooked in consensus models that assume a sharper inflection.
2. **Elevated short interest** (4.73%) is a leading indicator of market caution, not fully reflected in sell-side estimates or guidance, and could amplify volatility if Q2 results disappoint.

## Scenarios for the Upcoming Quarter

### Scenario Table

| Scenario | Revenue Estimate | Adjusted EPS | Gross Margin | Key Assumptions                                              |
|----------|------------------|--------------|--------------|--------------------------------------------------------------|
| Bull     | $3.30B           | $0.55        | 38%          | Swift regulatory resolution; early new product ramp          |
| Base     | $3.25B           | $0.50        | 36%          | Modest pipeline contribution; continued mild margin pressure |
| Bear     | $3.20B           | $0.45        | 35%          | Prolonged regulatory drag; slow product uptake               |

**Most Likely:** The **Base case** is most probable, given current evidence of gradual pipeline progress, ongoing margin pressure, and management’s measured tone.

## Appendix – Data Tables & Management Quotes

### Quarterly Revenue, EPS, and Margin Trends

| Quarter    | Revenue ($B) | Gross Margin | Operating Margin | Adjusted EPS |
|------------|--------------|--------------|-----------------|--------------|
| Q2 2024    | 3.32         | 41%          | 18%             | $0.58        |
| Q3 2024    | 3.28         | 39%          | 16%             | $0.54        |
| Q4 2024    | 3.27         | 37%          | 15%             | $0.52        |
| Q1 2025    | 3.25         | 36%          | 13%             | $0.50        |

### KPI Movement Table

| KPI                  | Q1 2024 | Q4 2024 | Q1 2025 | YoY Change | QoQ Change |
|----------------------|---------|---------|---------|------------|------------|
| New Product Revenue  | $55M    | $60M    | $67M    | +22%       | +12%       |
| Capex ($M)           | $120    | $110    | $102    | -15%       | -7%        |
| FCF ($M)             | $410    | $390    | $357    | -13%       | -8%        |

### Key Management Quotes

1. **“We are seeing early signs of normalization in demand and are well positioned for the next phase of growth.”**  
   *Q1 2025 Earnings Call*  
   *Interpretation: Management expects gradual improvement, but not an immediate rebound.*

2. **“Uncertainty and volatility remain, particularly in our core generics segment.”**  
   *Q1 2025 Earnings Call*  
   *Risk: Ongoing pricing and regulatory risks could weigh on results.*

3. **“We have revised our full-year adjusted EPS guidance upward to $2.16–$2.30.”**  
   *Q1 2025 Earnings Call*  
   *Interpretation: Confidence in pipeline and cost actions, but guidance still brackets risk.*

4. **“The impact from the Indore facility is expected to reduce annual revenue by $500M.”**  
   *Q1 2025 Earnings Call*  
   *Risk: Regulatory headwinds remain a material drag.*

5. **“New product launches contributed $67M in Q1, and we expect this to accelerate in the second half.”**  
   *Q1 2025 Earnings Call*  
   *Interpretation: H2 2025 could see a more meaningful revenue inflection.*

6. **“We are prioritizing liquidity and have reduced Capex by 15% year-over-year.”**  
   *Q1 2025 Earnings Call*  
   *Risk: Investment constraints may limit near-term growth initiatives.*

7. **“We remain focused on operational recovery and pipeline advancement in Q2.”**  
   *Q1 2025 Earnings Call*  
   *Interpretation: Execution on these fronts is critical for Q2 upside.*

---

**Bottom Line:**  
Viatris enters Q2 2025 with a stable revenue base but faces persistent margin headwinds and regulatory risks. While pipeline progress and regional growth offer upside, the path to recovery is likely to be gradual. Investors should watch for early signs of new product acceleration and regulatory resolution as key swing factors for the quarter.

Viatris (VTRS): Margin Pressures vs. Pipeline Upside